Andrew Moreno

DocwireNews

A team of investigators engaged in chimeric antigen receptor (CAR) T-cell therapy research has explored how AI-driven tools can enhance efficiency and insight distillation in this research. Their work is featured within late-breaking research presented at the American Association for Cancer Research Annual Meeting 2025 in Chicago, Illinois.The team searched the publicly available clinical literature on multiple myeloma (MM) CAR T-cell therapies using two AI-driven tools: BiblioEngine from 23Strands and Cool.AF from Neural Hinge. They used these tools to digest the vast information on therapies&rsquo; manufacturing processes, clinical trial designs, and their ultimate therapeutic applications. They also examined the therapies&rsquo; patents in the European Union, India, and the US Patent and Trademark Office.The two tools helped the team quickly sift through and compare datasets, finding trends in the design of clinical trials for CAR T-cell therapies and how the therapies are being used in clinical practice. They identified factors that led to patent success for the therapies and mapped out the current collaboration connections among authors of the examined literature.With these findings from the AI-based analysis, the team was able to pinpoint unmet needs in MM care and opportunities for patent filing. They found that the insights from the analysis can inform the structuring of clinical trials for MM CAR T-cell therapies and the filing of patents in a manner that is careful to avoid intellectual property conflicts. The analysis also included possibilities for new connections between published researchers to grow the network of collaborations and amplify current work in CAR T-cell therapy development.ReferenceAACR Annual Meeting 2025. Section #51. <a href="https://www.abstractsonline.com/pp8/#!/20273/presentation/9835">https://www.abstractsonline.com/pp8/#!/20273/presentation/9835</a>

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

AI-Driven Tools Enhance CAR T-Cell Therapy Research, Patent Filing

Hematology

Investigators used two AI-driven tools to analyze multiple myeloma therapies' clinical literature and patent information.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe